



Under the Paperwork Reduction Act of 1993, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB (12-97)  
OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

|  |  |   |
|--|--|---|
| Modified Form 1449/PTO<br><b>SUPPLEMENTAL<br/>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br>(use as many sheets as necessary) |  | Application Number<br>10/616,649          |
|  |  | Filing Date<br>07/09/03                   |
|  |  | First Named Inventor<br>Chiao             |
|  |  | Group Art Unit / Conf. No.<br>1614 / 9975 |
|  |  | Examiner Name<br>Not Yet Assigned         |
|  |  | Attorney Docket Number<br>24852-501 CIP2  |

| U.S. PATENT DOCUMENTS |          |                          |            |  |       |           |             |
|-----------------------|----------|--------------------------|------------|--|-------|-----------|-------------|
| Exam Initials         | Cite No. | U.S. Patent Document No. | Issue Date | Name of Patentee(s) or Applicant(s)  | Class | Sub Class | Filing Date |
| MG                    | A25*     | 4,690,918                | 09/01/87   | Beppu, et al.  |       |           |             |
|                       | A26*     | 5,654,333                | 08/05/97   | The United States of America as represented by the Department of Health and Human Services |       |           |             |
|                       | A27*     | 6,239,176                | 05/29/01   | Beacon Laboratories, Inc. et al.   |       |           |             |
|                       | A28*     | 6,262,116                | 07/17/01   | Sloan-Kettering Institute for Cancer Research  |       |           |             |
|                       | A29*     | 6,451,334                | 09/17/02   | Perrine  |       |           |             |
|                       | A30*     | 6,495,719                | 12/17/02   | CircaGen Pharmaceutical  |       |           |             |
|                       | A31*     | 2003/0114525             | 06/19/03   | Kammer, et al.   |       |           |             |
|                       | A32*     | 2004/0132643             | 07/08/04   | Fojo, et al.   |       |           |             |
|                       | A33*     | 2004/0167184             | 08/26/04   | Wiech, et al.  |       |           |             |
| MG                    | A34      | 6,495,719                | 12/17/02   | Lan-Hargest, et al.  |       |           |             |

| FOREIGN PATENT DOCUMENTS |          |                                |           |  |                     |             |    |
|--------------------------|----------|--------------------------------|-----------|--|---------------------|-------------|----|
| Exam Initials            | Cite No. | Foreign Patent Document Office | Number    | Name of Patentee(s) or Applicant(s)            | Date of Publication | English Yes | No |
| MG                       | B14*     | WO                             | 98/39965  | Beacon Laboratories, LLC                       | 09/17/98            | X           |    |
|                          | B15*     | WO                             | 02/15921  | The Government of the United States of America | 02/28/02            | X           |    |
| MG                       | B16*     | WO                             | 02/055017 | Wake Forest University                         | 07/18/02            | X           |    |

| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS |          |  |
|---|----------|--|
| Exam Initials                                     | Cite No. | Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.   |
| MG  | C83*     | "Aton Pharma, Inc. Announces Initiation of Two Phase II Trials to Evaluate Efficacy of HDAC Inhibitor SAHA", October 30, 2002.             |
|   | C84*     | "Aton Pharma, Inc. Announces Phase I Clinical Trial of SAHA in Advanced Leukemias", July 1, 2003.  |
|   | C85*     | "Aton Pharma, Inc. Appoints Judy H. Chiao, M.D., as Vice President; Oncology Clinical Research and Development", September 20, 2002.       |
|   | C86*     | "Aton Pharma, Inc. Presents Phase I Trial Data of Anti-Cancer Agent SAHA in Patients with hematological Malignancy at ASCO", June 2, 2003. |
|   | C87*     | "Aton Pharma, Inc. Presents Phase I Trial Data on Anti-Cancer Agent SAHA at EORTC/NCI/AACR Symposium", November 21, 2002.                  |
| MG  | C88*     | "Aton Pharma, Inc. Received Orphan Drug Designation for SAHA in Multiple Myeloma and Initiates Phase I                                     |